SGN-35

SGN-35 is an antibody-drug conjugate (ADC) used in the treatment of certain types of cancer. It is also known by its generic name, brentuximab vedotin. SGN-35 is primarily used to treat Hodgkin lymphoma and systemic anaplastic large cell lymphoma (sALCL).

Mechanism of Action[edit | edit source]

SGN-35 works by combining a monoclonal antibody with a cytotoxic agent. The monoclonal antibody component of SGN-35 specifically targets the CD30 antigen, which is expressed on the surface of certain cancer cells. Once SGN-35 binds to the CD30 antigen, it is internalized by the cancer cell. Inside the cell, the cytotoxic agent, monomethyl auristatin E (MMAE), is released, leading to cell cycle arrest and apoptosis.

Clinical Use[edit | edit source]

SGN-35 has been approved for the treatment of:

Hodgkin lymphoma after failure of autologous stem cell transplant or after failure of at least two prior multi-agent chemotherapy regimens in patients who are not candidates for autologous stem cell transplant.
Systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen.

Side Effects[edit | edit source]

Common side effects of SGN-35 include:

Development and Approval[edit | edit source]

SGN-35 was developed by Seattle Genetics in collaboration with Millennium Pharmaceuticals. It received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2011 for the treatment of Hodgkin lymphoma and systemic anaplastic large cell lymphoma.